Last updated: February 15, 2024
Sponsor: EMS
Overall Status: Active - Recruiting
Phase
3
Condition
Hypertriglyceridemia
Dyslipidemia
Treatment
Crestor 10 mg
Cipros 10 association
Clinical Study ID
NCT03527069
EMS0617-CIPROS
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Participants of both sexes, aged 18 years or more;
- Participants with the diagnosis of Dyslipidemia presentinf low or intermediatecardiovascular risk, according to the Brazilian Guidelines on Dyslipidemia andPrevention of Atherosclerosis;
- Signed consent.
Exclusion
Exclusion Criteria:
- Diagnosis of familial hypercholesterolemia and other genetic diseases;
- Using medications that may interfere with the metabolism or serum levels oftriglycerides;
- Any clinical and laboratory findings that, in the judgment of the investigator, mayinterfere with the safety of research participants;
- Presence of concomitant cardiovascular disease, renal failure and hepatic Failure;
- Decompensated diabetes;
- Current smoking;
- History hypersensitivity to the active ingredients used in the study;
- Pregnancy or risk of pregnancy and lactating patients;
- History of alcohol abuse or illicit drug use;
- Participation in clinical trial in the year prior to this study.
Study Design
Total Participants: 298
Treatment Group(s): 2
Primary Treatment: Crestor 10 mg
Phase: 3
Study Start date:
January 29, 2021
Estimated Completion Date:
February 28, 2025
Connect with a study center
Allergisa
Campinas, São Paulo
BrazilActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.